A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects (clinicaltrials.gov) - May 19, 2023 - P1 | N=18 | Recruiting | Sponsor: Endeavor Biomedicines, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
|